The Family Medicine Channel

Kidney Cancer Vaccine Disappoints

:51 | Family Medicine, Oncology, Oncology / Hematology, Surgery, Urology

The tumor-derived vaccine vitespen (Oncophage) does not prevent renal-cell carcinoma recurrence or improve survival despite promising early results.

References and Resources
Wood C, Srivastava P, Bukowski R, et al. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet. 2008 July(5):213-17.

More in Family Medicine

► 2:21:57

Virtual Conference: ISEH Adolescent Sports Medicine

Family Medicine

At the ISEH Adolescent Sports Medicine virtual conference, the speakers discussed common upper and lower limb problems, concussion management, and respiratory and breathing concerns in adolescents. Additional topics included managing...

► 1:04:07

The Reliability and Transferability of Current Randomized Controlled Trials Based on Real-World Evidence

Dermatology

Robert Kirsner, MD, PhD, University of Miami, Florida; Oscar M. Alvarez, PhD, Rutgers New Jersey Medical School, Newark, New Jersey; Vickie R. Driver, DPM, MS, INOVA Health System, Alexandria, Virginia;...

►

Physician Burnout: Addressing the Rapid Increase

Business of Medicine

Todd Unger, chief experience officer, AMA, and Christine Sinsky, MD, the AMA's vice president of professional satisfaction, discuss a recent study on physician burnout. Dr Sinsky explained that physician burnout...

► 58:01

Street Medicine: Why, What, How

Family Medicine

For the inaugural Macaran A. Baird, MD, Lecture in Family Medicine and Community Health Leadership, Jehni Robinson, MD, chair and clinical professor of the Department of Family Medicine and associate...